TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aspergillosis
Scientists at Medical University of South Carolina target aspergillosis
June 23rd, 2009
According to a study from the United States, "We report a case of allergic bronchopulmonary aspergillosis (ABPA) that occurred in a man receiving infliximab for systemic sarcoidosis." "His symptoms associated with ABPA were temporally related to his infliximab infusions," wrote M.A. Judson and colleagues, Medical University of South Carolina. The researchers concluded: "We suspect that infliximab disrupted the T-helper (Th) type 1-Th2 lymphocyte balance such that Th2 cytokines were left relatively unopposed, promoting the development of ABPA. (CHEST 2009; 135:1358-1359)'." Judson and colleagues published the results of their...
Source: TB & Outbreaks Week (2009-06-23)
|
